Array stock: buy or sell?

ARRY stock price: $47.85 0.00% At close on July 30th, 2019

Updated on:
July 30th, 2019


After several days of continuous hikes in past weeks, Array remained steady 0.00% to $47.85. With July, it's been 3 green sessions in a row, adding $0.93 or 1.98%.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.

Should I buy Array stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, 2 buy setups are elegible for Array stock now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Array BioPharma stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we collected 15 ratings published for ARRY stock in the last month.

Is ARRY a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-7-8Cantor FitzgeraldOverweightNeutral
2019-7-12JPMorgan Chase & Co.OverweightNeutral
2019-6-18Svb LeerinkOutperformMarket Perform
2019-6-18Leerink SwannOutperformMarket Perform
2019-6-18Goldman Sachs Groupn/aNeutral
2019-6-17Wells Fargo & CoOutperformMarket Perform
2019-6-17SunTrust BanksBuyHold
2019-6-17Piper Jaffray CompaniesOverweightNeutral
2019-6-17Jefferies Financial GroupBuyHold
2019-5-22SunTrust Banksn/aBuy
2019-5-21Piper Jaffray Companiesn/aOverweight
2019-3-14JPMorgan Chase & Co.PositiveOverweight
2019-1-17Leerink Swannn/aOutperform
2019-1-15Piper Jaffray CompaniesOverweightPositive

Array stock analysis

Daily outlook

After several days of continuous hikes in past weeks, Array remained steady 0.00% to $47.85.

After reaching all time highs on July, Array BioPharma remained constant 0.00% to $47.85. ARRY broke out again over $47.01 after a 1.68% correction started on July. On May ARRY price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock. On July, ARRY hit a new all time high, pushing higher than on July tops. Check different trading setups that use ATHs as triggers.

ARRY stock chart (daily)

Weekly outlook

Array shares peaked new all time highs back again this week, marking to $47.98. Shares ended at $47.85 and gained 1.18% during the week. By mid June ARRY skyrocketed an astounding 35.95% in just one week.

Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $47.05 resistance. Since SMA20d and SMA40w crossed up early February, ARRY price climbed $28.65 per share (149.22%). Late December 2018 ARRY price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

ARRY stock chart (weekly)

Array stock price history

Array IPO was on November 30th, 2000 at $8.75 per share1. Since then, ARRY stock grew a 446.90%, with an average of 24.80% per year. If you had invested $1,000 in Array stock in 2000, it would worth $4,469.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Array stock historical price chart

ARRY stock reached all-time highs on July with a price of $47.98.

Array stock price target is $36.80

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 9 price forecasts for Array stock:
ARRY stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-8Cantor FitzgeraldDowngrades$34.00$48.0041.2%
2019-7-12JPMorgan Chase & Co.Downgrades$29.00$48.0065.5%
2019-6-18Svb LeerinkReiterates$32.00$48.0050%
2019-6-18Goldman Sachs GroupRaises Target$27.00$38.0040.7%
2019-5-22SunTrust BanksRaises Targetn/a$32.00-
2019-5-21Piper Jaffray CompaniesReiterates$28.00$35.0025%
2019-3-14JPMorgan Chase & Co.Reiterates$18.00$29.0061.1%
2019-1-15Piper Jaffray CompaniesReiteratesn/a$28.00-
(in average)$28.00$36.8031.0%
Moving in a range from $48.00 and $25.00, the price target for ARRY stock is $36.80. In average, analysts' outlook on ARRY price target is positive, increasing the forecast by a 31.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Array let down analysts on February when it reported an Earnings per Share (EPS) of $-0.05 when the market consensus was $-0.16.
ARRY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Array BioPharma annual revenues rocketed an extraordinary 15.19% to $173.77 M dollars from $150.85 marked in 2017. In contrary, its profit margin (compared to sales) dropped to -84.79%, that is $-147.35 million.

To have an up to date view of the financial situation of Array, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual Array TTM sales up to December 2018 were $241.26 and income was $-111.47 million dollars. When comparing this TTM figures with the last reported annuality, we can review Array BioPharma business evolution since June 2018: Annual sales up to December, compared to lastest yearly report, boosted an amazing 38.84%. In line, profit margin (net income/revenues) climbed at -84.79%.

ARRY annual Sales and Income evolution
2013$70 M-$-61.94 M-89.0%-
2014$42 M-39.52%$-85.26 M-202.6%37.65%
2015$52 M23.36%$9.37 M18.0%-110.99%
2016$138 M165.62%$-92.84 M-67.3%-1,090.93%
2017$151 M9.41%$-116.82 M-77.4%25.83%
2018$174 M15.19%$-147.35 M-84.8%26.13%
TTM $241 M38.84%$-111.47 M-46.2%-24.35%

Quarterly financial results

Array reported $82.55 million in sales for 2018-Q4, a 45.05% up compared to previous quarter. Reported quarter earnings marked $-11.36 M with a profit margin of -13.76%. Profit margin skyrocketed a 29.83% compared to previous quarter when profit margin was -43.60%. When comparing revenues to same quarter last year, Array BioPharma sales marked an exceptional increase and climbed a 95.53%. Looking back to recent quarterly results, Array posted 2 positive quarters in a row.
ARRY quarterly Sales and Income evolution
2017-Q1$33 M-$-35.32 M-106.1%-
2017-Q2$34 M1.50%$-29.59 M-87.6%-16.22%
2017-Q3$30 M-11.94%$-37.99 M-127.7%28.40%
2017-Q4$42 M41.93%$-34.05 M-80.7%-10.37%
2018-Q1$66 M57.20%$-22.85 M-34.4%-32.90%
2018-Q2$35 M-46.60%$-52.45 M-148.0%129.52%
2018-Q3$57 M60.59%$-24.81 M-43.6%-52.69%
2018-Q4$83 M45.05%$-11.36 M-13.8%-54.21%

Array ownership

When you are planning to buy a stock, it's worth to review its ownership structure.

Array shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.

The following table compares ownership indicators for other stocks related to Array:

Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

Array summary

Tuesday, July 30th, 2019
Day range$47.84 - $47.98
Previous close$47.85
Session gain0.00%
Average true range$0.38
50d mov avg$39.37
100d mov avg$31.28
200d mov avg$24.31
Daily patternlb01c
Weekly pattern lb02c

Array performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Array BioPharma performance to :
ARRYArray BioPharma106.52%149.22%216.47%

Array competitors

Unfortunately, we could not find any public company that could be defined as Array competitor. This doesn't mean Array does not have any competitor in the market, it's just we could not detected it.